** Brokerage Guggenheim raises PT on drug developer Travere Therapeutics to $45 from $41
** New PT represents a 142% upside to the stock's Monday close
** TVTX's Filspari is an FDA-approved drug for the treatment of IgA nephropathy (IgAN), a type of disease where a protein called IgA builds up in the kidneys, causing inflammation
** On Monday, TVTX reported $50 mln in preliminary Filspari net product sales in 4Q 2024, which is "somewhat above investor expectations" of $45 mln, brokerage says
** Brokerage says it is "increasingly optimistic" about Filspari's potential in IgAN and its potential label expansion to Focal Segmental Glomerulosclerosis $(FSGS)$, a type of kidney disease, representing a $2 bln peak sales opportunity in the U.S.
** Brokerage forecasts annual U.S. Filspari sales for 2025 at $266 mln
** TVTX gained ~82 in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.